CBD Pet Products Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global CBD Pet Products Market Trends and Insights

Increasing Incidence of Chronic Disorders in Pets

Degenerative joint disease, epilepsy, and anxiety now afflict a sizable share of aging companion animals, prompting sustained demand for non-pharmaceutical interventions^{[1]Source: American Holistic Veterinary Medical Association, “2024 Member Survey,” AHVMA.ORG}. Owners worry about the hepatotoxicity of long-term NSAID use and are turning to cannabinoid-based solutions that interact with CB1 and CB2 receptors. Clinical trials reported a 35% pain-score reduction in osteoarthritic dogs given full-spectrum CBD at 2 mg/kg twice daily, without liver-enzyme elevation. These outcomes nurture veterinary confidence and widen prescriptive adoption. The trend is especially evident in North America, where 40% of dogs aged seven years or older exhibit chronic arthritis symptoms. Parallel patterns emerge across Europe, positioning CBD as a bridge therapy for refractory conditions. The resulting uptick in daily dosing drives repeat purchases and strengthens lifetime customer value.

Rising Pet Ownership and Humanization Trends

In 2024, 67% of American households owned at least one pet, marking a significant increase from 2021^{[2]Source: American Veterinary Medical Association, “U.S. Pet Ownership Statistics,” AVMA, AHVMA.ORG}. Millennials and Gen Z lead this expansion and treat animals as family, allocating monthly budgets of USD 60-120 for CBD treats in lieu of generic supplements costing one-third as much. Comparable sentiment in Germany, where pet ownership penetration reached 47% in 2024, reinforces tolerance for premium pricing. These consumers actively research ingredients, prefer organic hemp, and reward brands that publish batch-level potency tests. Social media amplifies personal testimonials, normalizing cannabidiol as a preventive wellness tool. As owners adopt adaptogen habits for their pets, demand for USDA-certified CBD tinctures increases across metropolitan areas worldwide.

Increased Focus and Expenditure on Pet Health and Wellness

Pet owners in North America spent significantly on veterinary care and wellness products during 2024, with preventive supplements accounting for a notable share of this spending. Growth aligns with rising pet-insurance penetration in the United States, with policies increasingly reimbursing alternative therapies such as CBD. Preventive positioning is critical, as brands market oils for daily maintenance of joint mobility and cognitive function before clinical symptoms appear. Insured owners perceive lower out-of-pocket risk, raising conversion rates. The dynamic is mirrored in Western Europe, where wellness subscriptions bundle CBD chews with routine flea protection, reinforcing monthly order cadence. Consequently, the CBD pet products market experiences stable baseline demand, insulating suppliers from seasonal volatility.

Expanding Retail and E-Commerce Channels That Allow CBD Sales

Amazon’s 2024 decision to list hemp-derived CBD for pets unlocked access to 200 million Prime subscribers. Chewy promptly followed, creating a curated storefront that highlights third-party lab reports, improving brand credibility. Brick-and-mortar giants Petco and PetSmart expanded their CBD assortments after favorable state guidelines reduced compliance uncertainty across multiple markets. Omnichannel presence compresses discovery barriers, allowing owners to add CBD products to existing shopping baskets rather than seeking specialty stores. Lower fulfillment costs and subscription discounts convert first-time buyers into repeat customers. The rapid scale achievable through online distribution positions digital-native brands to challenge legacy veterinary-clinic channels and capture incremental share in the CBD pet products market.

High Cost of Premium CBD Pet Products

Full-spectrum organic CBD oils retail at USD 0.15-0.25 per milligram, roughly triple the cost of glucosamine-chondroitin supplements, creating affordability barriers in emerging economies. A month-long CBD regimen for a medium-sized dog can be costly, positioning cannabidiol as a discretionary luxury rather than a staple. Upstream expenses include certified-organic cultivation, supercritical CO₂ extraction, and batch-level contaminant screening, all of which contribute significantly to production costs. When regulators do not mandate testing, price-sensitive owners often choose cheaper, uncertified products or abandon CBD altogether. Consequently, penetration remains low across South America and Africa, where disposable incomes are constrained. Persistent cost differentials in the CBD pet products market temper volume growth despite rising global awareness. 

Stringent Regulatory Requirements for Product Approval

The Food and Drug Administration lacks a defined pathway for CBD pet products, creating compliance ambiguity that invites warning letters and stifles marketing claims^{[3]Source: U.S. Food and Drug Administration, “Regulation of Cannabis and Cannabis-Derived Products,” FDA.GOV}. European Medicines Agency novel-food dossiers require extensive toxicology and stability studies, favoring well-capitalized firms and delaying entry for smaller brands. Even Australia’s recently streamlined Schedule 4 route mandates pharmacokinetic submissions. Lengthy approval timelines consume capital and create uncertainty that may deter investors. Firms unable to meet data requirements risk delisting or forced reformulation. These regulatory frictions slow SKU refresh cycles and limit the breadth of therapeutic indications offered within the CBD pet products industry.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Therapeutic-Grade Oils Drive Premium Positioning

Therapeutic-grade oils captured 55% of the 2025 value, followed by food-grade treats, while personal-care topicals accounted for the remainder. Concentrated tinctures with 300-1,500 mg cannabidiol per bottle lead the CBD pet products market because they allow weight-based dose titration. Food-grade chews maintain share by masking hemp taste, yet they suffer lower bioavailability. Topicals remain niche but appeal to owners treating localized dermatitis without oral administration.

Therapeutic-grade oils will post a 15.4% CAGR through 2031, the fastest within the category, propelled by nano-emulsion technologies that cut onset time to 15 minutes. Food-grade treats are estimated to grow strongly, supported by new flavors and soft-chew formats. Topicals are also projected to expand steadily as veterinary dermatology increasingly embraces cannabinoid-infused shampoos and balms.

By Animal Type: Canine Dominance Faces Feline Disruption

Dogs contributed 61% of 2025 revenue, followed by cats, while other pets contributed a smaller share. Large-breed dogs consume more CBD per dose to manage osteoarthritis and anxiety, anchoring canine leadership in the CBD pet products market. Cats remained below one-third share because early coconut-oil carriers impaired palatability.

Cats will expand at a 14.8% CAGR to 2031, outstripping other species after fish-oil-based tinctures improved acceptance. Dogs are projected to grow strongly, supported by increasing insurance coverage for chronic pain management. Other pets, including horses and rabbits, are also estimated to expand steadily, driven by demand from performance-horse segments and the growth of specialty e-commerce offerings for exotic pets.

By Distribution Channel: E-Commerce Rewrites Access Economics

Online retail held 41% of 2025 spend, and veterinary clinics, retail pharmacies, and pet stores represent significant distribution channels. Digital channels, however, dominate the CBD pet products market by offering subscription discounts, rapid consumer education, and easy display of product certifications. Clinics leverage professional trust but face stocking hesitancy. Physical pet stores benefit from impulse buys but must comply with varying state rules.

Online retail will surge at 18.7% CAGR to 2031, far ahead of offline formats. Veterinary clinics are estimated to grow strongly as greater legal clarity boosts in-house sales. Retail pharmacies and pet stores are likely to trail, constrained by ongoing regulatory checks and increasing competition from direct-to-consumer brands.

Geography Analysis

North America generated 48% of 2025 revenue and is estimated to continue expanding at a strong pace. United States households spend an average of USD 1,480 per pet annually and readily adopt organic CBD oils endorsed by veterinarians. Canada’s 2024 Cannabis Act amendments removed pre-market hurdles for hemp-derived pet products, letting provincial chains stock CBD alongside traditional supplements. Mexico is estimated to issue formal guidelines by 2027, unlocking pent-up demand currently served through gray imports.

Asia-Pacific is forecast to grow at 15.1% CAGR, the highest among all regions. Australia reclassified low-THC CBD as Schedule 4 in 2025, enabling prescription fulfillment through pharmacies and fueling immediate volume gains. China’s draft hemp-supplement regulations signal market opening in a country with rising middle-class expenditure and pet population. India awaits Food Safety and Standards Authority clarity, yet rising urban pet ownership is flagging a latent market opportunity once rules crystallize.

Europe will advance at a strong pace. Germany, the United Kingdom, France, and Spain together represent the majority of regional spend. Stricter Veterinary Medicines Directorate rules in the United Kingdom slow product launches but elevate overall quality standards, while Germany’s guidance excluding low-THC hemp extracts from narcotic regulations streamlines distribution. South America is also estimated to expand steadily, led by Brazil’s over-the-counter approval framework for CBD pet oils. Africa remains a nascent market, while South Africa’s prescription-only stance confines distribution primarily to licensed veterinary practices.

Regulatory Landscape

In the United States, CBD-containing pet products continue to face a constrained regulatory pathway at the federal level. The US Food and Drug Administration (FDA) has not approved or indexed any animal drug containing CBD, and products promoted for prevention or treatment of animal disease are treated as unapproved animal drugs subject to enforcement actions. For products positioned as animal food, CBD is not an authorized ingredient (it is not AAFCO-defined, GRAS, or an approved food additive), which keeps marketing claims, labeling, and distribution practices under close scrutiny even as hemp cultivation is governed separately under USDA hemp standards.

In Europe, CBD inclusion in animal feed is not authorized under Regulation (EC) No 1831/2003 for feed additives, and pathways tied to EU novel food and EFSA safety assessment have not delivered an approval that enables broad pet-market placement. In February 2026, the European Commission formally terminated a cannabidiol novel-food authorization procedure due to insufficient supporting data, reinforcing the region's high evidentiary bar. This fragmented compliance environment also raises the importance of veterinary practice rules (for example, state-level guidance linked to the veterinarian-client-patient-relationship in the US), which shapes how brands handle education, claims, and channel strategy.

Market Opportunities and Future Outlook

The strongest opportunity set centers on compliant, evidence-forward product positioning and quality infrastructure that fits current enforcement realities. FDA action against therapeutic claims and non-authorized animal-food uses has pushed brands toward tighter labeling discipline, expanded third-party testing, and clearer certificates of analysis. This direction aligns with how online retail curation is evolving, including storefront models that emphasize lab reports and traceability. The Federal Register FDA request for information released in January 2025 on cannabis-derived products in veterinary use also signals that data collection on safety and use conditions is moving forward, which gives well-capitalized brands a way to differentiate with toxicology, stability, and pharmacokinetic packages.

Geographic whitespace remains visible in places where commercialization routes look clearer. In Australia, low-THC CBD was reclassified as Schedule 4 in 2025, enabling prescription fulfillment through pharmacies. In Canada, the 2024 Cannabis Act amendments reduced pre-market hurdles for hemp-derived pet products in provincial retail. On product demand, therapeutic-grade oils remain a key format for precise dosing and repeat purchase economics, while formulation improvements such as nano-emulsions and palatability-focused carriers support species-specific dosing guidance for cats and senior-dog chronic conditions. Brands that pair compliant claims frameworks with channel execution in e-commerce and vet-adjacent distribution can scale without relying on broad disease-treatment positioning that tends to carry higher regulatory risk.